Therefore, the model we developed includes most of the possible crucial IRPSs, and we have identified two IRPSs (TMB and KRAS mutations) that can accurately predict the clinical outcomes of patients with advanced NSCLC from Qujing and effectively differentiate ICI-sensitive patients. This evidence concerns the gene KRAS and non-small cell lung carcinoma.